Cart
sales@molnova.com
IMMH 010 maleate
CAS No. 2541982-47-0
IMMH 010 maleate( —— )
Catalog No. M37361 CAS No. 2541982-47-0
IMMH 010 maleate (YPD-30 maleate) is an orally available programmed cell death ligand 1 inhibitor with potential antitumor activity for the study of neurological disorders and advanced malignant solid tumors.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 296 | Get Quote |
|
| 5MG | 459 | Get Quote |
|
| 10MG | 657 | Get Quote |
|
| 25MG | 994 | Get Quote |
|
| 50MG | 1371 | Get Quote |
|
| 100MG | 1773 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameIMMH 010 maleate
-
NoteResearch use only, not for human use.
-
Brief DescriptionIMMH 010 maleate (YPD-30 maleate) is an orally available programmed cell death ligand 1 inhibitor with potential antitumor activity for the study of neurological disorders and advanced malignant solid tumors.
-
DescriptionIMMH 010 maleate (YPD-30 maleate) is an orally available programmed cell death ligand 1 inhibitor with potential antitumor activity for the study of neurological disorders and advanced malignant solid tumors.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayImmunology/Inflammation
-
TargetPD-1/PD-L1
-
RecptorPD-1/PD-L1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2541982-47-0
-
Formula Weight756.04
-
Molecular FormulaC36H36BrClN2O9
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(=C\C(O)=O)\C(O)=O.O(CC=1C=CC=NC1)C2=C(CN[C@H](C(OC(C)C)=O)CO)C=C(Cl)C(OCC3=C(Br)C(=CC=C3)C4=CC=CC=C4)=C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
PD-1/PD-L1-IN-10
PD-1/PD-L1-IN-10 is an orally active?PD-1/PD-L1?inhibitor (IC50?of 2.7 nM) with potent anticancer efficacy.
-
BMS-200
A potent PD-1/PD-L1 interaction inhibitor with IC50 of 80 nM in a homogenous time-resolved fluorescence binding assay.
-
Durvalumab
Durvalumab (MEDI 4736) is a humanized monoclonal antibody targeting PD-L1. It can block the interaction of PD-L1 with PD-1 and CD80, with IC50 values of 0.1 and 0.04 nM, respectively.
